Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens

We report on the in vitro activity of the Hos2 fungal histone deacetylase (HDAC) inhibitor MGCD290 (MethylGene, Inc.) in combination with azoles against azole-resistant yeasts and molds. Susceptibility testing was performed by the CLSI M27-A3 and M38-A2 broth microdilution methods. Testing of the co...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Clinical Microbiology 2009-12, Vol.47 (12), p.3797-3804
Main Authors: Pfaller, M.A, Messer, S.A, Georgopapadakou, N, Martell, L.A, Besterman, J.M, Diekema, D.J
Format: Article
Language:English
Subjects:
Antifungal Agents - pharmacology
Aspergillus
Biological and medical sciences
Candida
Cryptococcus neoformans
Drug Resistance, Fungal
Drug Synergism
Drug Therapy, Combination
Fundamental and applied biological sciences. Psychology
Fungi - classification
Fungi - drug effects
Fusarium
Histone Deacetylase Inhibitors - pharmacology
Humans
Microbial Sensitivity Tests
Microbiology
Mucor
Mycology
Mycoses - drug therapy
Mycoses - microbiology
Opportunistic Infections - drug therapy
Opportunistic Infections - microbiology
Rhizopus
Rhodotorula
Scedosporium
Triazoles - pharmacology
Trichosporon
Zygomycetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report on the in vitro activity of the Hos2 fungal histone deacetylase (HDAC) inhibitor MGCD290 (MethylGene, Inc.) in combination with azoles against azole-resistant yeasts and molds. Susceptibility testing was performed by the CLSI M27-A3 and M38-A2 broth microdilution methods. Testing of the combinations (MGCD290 in combination with fluconazole, posaconazole, or voriconazole) was performed by the checkerboard method. The fractional inhibitory concentrations were determined and were defined as
ISSN:0095-1137
1098-660X
DOI:10.1128/JCM.00618-09